

Resource Summary Report

Generated by NIF on Jul 30, 2026

HLA-DR (SPM289)

RRID:AB_1125217

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-56545, RRID:AB_1125217

Antibody Information

URL: http://antibodyregistry.org/AB_1125217

Proper Citation: Santa Cruz Biotechnology Cat# sc-56545, RRID:AB_1125217

Target Antigen: HLA-DR (SPM289)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunofluorescence; Immunohistochemistry; Immunocytochemistry; Immunoprecipitation; Western Blot; Flow Cytometry; WB, IP, IF, IHC(P), FCM

Antibody Name: HLA-DR (SPM289)

Description: This monoclonal targets HLA-DR (SPM289)

Target Organism: human

Antibody ID: AB_1125217

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-56545

Record Creation Time: 20250820T041224+0000

Record Last Update: 20250820T182007+0000

Ratings and Alerts

No rating or validation information has been found for HLA-DR (SPM289).

No alerts have been found for HLA-DR (SPM289).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pozniak J, et al. (2024) A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. *Cell*, 187(1), 166.

Bosisio FM, et al. (2020) Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. *eLife*, 9.